Get Access →
Live • 4,280 trials tracked • FDA • EMA • WHO

Decode the future of drugs before the market does.

DrugInsight turns fragmented clinical, regulatory and commercial data into clear decisions. Track pipelines, predict approvals, spot safety signals and benchmark every molecule — in real time.

Explore Platform → What is DrugInsight?
12,400+Drugs & biologics profiled
98.2%Approval prediction accuracy
64Countries regulatory coverage
24/7Signal monitoring
Modern pharmaceutical laboratory
✔ FDA Fast Track granted
GLP-1 + GIP dual agonist • Phase 3
+34.2% efficacy signal
Oncology • ADC • n=1,240
CLINICAL TRIALS ● DRUG PIPELINE ● PHARMACOVIGILANCE ● FDA APPROVALS ● BIOTECH ● REAL-WORLD EVIDENCE ● MARKET FORECAST ● CLINICAL TRIALS ● DRUG PIPELINE ● PHARMACOVIGILANCE ● FDA APPROVALS ● BIOTECH ● REAL-WORLD EVIDENCE ● MARKET FORECAST ●
Scientist analyzing drug data Lab research Pharmacy and pills
01 — About DrugInsight

We were built because drug data was broken.

DrugInsight.com started as a research newsletter tracking overlooked clinical readouts. Today it is an intelligence OS used by biotech founders, investors, pharmacists, physicians and market analysts to see what’s coming 12–36 months before labels change.

We aggregate ClinicalTrials.gov, FDA, EMA, WHO ATC, DailyMed, patent filings, adverse event reports and payer data — then our models clean, link and score every asset by efficacy, safety, novelty and commercial potential.

✓Independent. No sponsored placements. No pharma advertising. Scores are algorithmic and auditable.
✓Explainable AI. Every prediction links to source trials, endpoints, p-values and regulatory documents.
✓Built for speed. From signal to alert in under 15 minutes. Daily briefs in plain English.
See how it works Read latest insights
2016Founded, Boston
42Scientists + data engineers
180kMonthly readers
02 — Platform

One dashboard for every drug question.

Stop jumping between 14 registries and PDFs. DrugInsight unifies discovery, trials, safety and commercial in one search.

🔬

Trial Radar

Live tracking of 4,280+ active trials with enrollment velocity, endpoint changes and interim readouts flagged automatically.

🧬

Molecule Profiler

Mechanism, targets, PK/PD, drug-drug interactions and repurposing opportunities for 12,400+ compounds.

⚠️

Safety Signals

FAERS + EudraVigilance mining with disproportionality analysis. Black-box warnings predicted 8 months early.

📈

Forecast Engine

Approval probability, peak sales, LOE cliffs and biosimilar risk modeled from 20 years of history.

Data analytics

Regulatory Copilot

FDA AdCom briefs, CRL autopsies, PDUFA calendars and EMA CHMP opinions summarized in 3 minutes. Never miss a Complete Response Letter pattern again. Includes Orange Book patent linkage and exclusivity timers.

Medical research

Real-World Evidence Layer

Claims + EHR-derived adherence, persistence and off-label use. See how GLP-1s, ADCs and cell therapies perform outside trials — by age, comorbidity and payer.

03 — Coverage

Therapeutic areas we obsess over.

Deep, not shallow. Each area has a dedicated curator + model tuned to its endpoints.

Oncology

Oncology & ADCs

ORR, PFS, OS cross-trial comparisons. TROP2, HER2, KRAS G12C, bispecifics. 1,120 assets tracked.

Cardiometabolic

Cardiometabolic & Obesity

GLP-1, GIP, glucagon, amylin. Weight, HbA1c, MACE durability and supply-chain watch.

Neuroscience

Neuroscience & Rare

Alzheimer anti-amyloid, Parkinson, epilepsy, gene therapies. ARIA, biomarker enrichment decoded.

Immunology

Immunology & Inflammation

IL-17, IL-23, TYK2, TL1A. PASI, ACR, CDAI head-to-heads and switching dynamics.

Infectious disease

Infectious & Vaccines

RSV, flu, COVID next-gen, antibiotics vs AMR. Strain coverage and effectiveness tracking.

Cell therapy

Cell & Gene Therapy

CAR-T, TIL, CRISPR, AAV durability, manufacturing failures and pricing models.

04 — Live Pipeline Snapshot

What Phase 3 looks like right now.

Illustrative snapshot refreshed daily from our engine. Full sortable table inside the platform.

Drug / CandidateIndicationPhasePDUFA / ReadoutInsight Score
Retatrutide (LY-3437943)
GGG tri-agonist • LillyObesityPhase 3Q2 202694 / 100
Datopotamab deruxtecan
TROP2 ADCNSCLC, BreastPhase 3Q1 202691 / 100
Donanemab follow-on
Anti-amyloidAlzheimerFDA ReviewDec 202584 / 100
TL1A inhibitor (tulisokibart)
Anti-TL1AIBDPhase 2bH1 202688 / 100
CRISPR sickle therapy
Ex vivo editingSCDApprovedLaunched79 / 100
Oral PCSK9 inhibitor
Small moleculeHyperlipidemiaPhase 2Q3 202682 / 100

How we score

Insight Score = 40% efficacy delta vs standard of care + 25% safety + 20% regulatory momentum + 15% commercial moat. Backtested on 1,800 approvals since 2004.

Alerts you actually read

Endpoint switched? Enrollment paused? FDA briefing doc dropped at midnight? You get a 5-line Slack + email with why it matters and what to check next.

05 — Insights & News

Latest analyses from the lab.

Deep dives, FDA previews and market breakdowns — updated daily by our editors and models.

No insights yet

Our editors are preparing the first batch of deep dives. Check back soon.

06 — Methodology

Rigorous enough for regulators. Clear enough for humans.

Every DrugInsight brief shows its work. No black boxes.

Methodology

1. Collect — 38 sources, deduplicated

ClinicalTrials.gov, CTIS (EU), FDA Drugs@FDA, DailyMed labels, EMA EPARs, patent Orange Book, FAERS, PubMed, payer formularies, earnings calls.

2. Link — one ID per molecule

INN, UNII, CAS, ATC and brand names resolved to a single DrugInsight ID. Biosimilars, combos and prodrugs correctly mapped.

3. Score — human + machine

LLMs extract endpoints; biostatisticians validate. Disagreements are flagged, not hidden. Inter-rater κ = 0.87.

4. Publish — with receipts

Every claim links to NCT number, FDA PDF page, or dataset row. Corrections log is public.

07 — Loved by operators

From bench to Bloomberg.

“DrugInsight flagged the endpoint switch 6 weeks before the stock moved. Paid for itself 100x.”

— Biotech PM, Boston

“The only newsletter our pharmacy & therapeutics committee actually reads. Safety summaries are gold.”

— Chief Pharmacist, EU hospital

“We killed a $2M program after their futility analysis. Painful, correct, and early.”

— Founder, Series A biotech

08 — FAQ

Questions, answered.

Is DrugInsight medical advice?
No. We provide information and analytics for education and research. Always consult a qualified clinician and the official label before making treatment decisions.
Where does the data come from?
Public registries (ClinicalTrials.gov, EU CTIS), regulators (FDA, EMA), labels (DailyMed), safety databases (FAERS, EudraVigilance), literature and commercial filings. All sources are cited.
How fresh is the pipeline data?
Trial registry deltas every 6 hours, FDA/EMA documents within 15 minutes of posting, safety signals nightly, forecasts weekly or on catalyst.
Do you cover my drug or indication?
Likely yes — 12,400+ profiles across 28 therapeutic areas. Use search inside the platform or request a custom deep dive via contact.
Can I use DrugInsight for investing?
Many subscribers do for idea generation and risk checks, but this is not investment advice. Catalyst predictions include confidence intervals and failure modes.

Get the DrugInsight Daily Brief — free for 14 days.

One email. Five drugs. Three catalysts. Zero fluff. Join 48,000+ clinicians, scientists and analysts.

No spam. Unsubscribe anytime. We never sell data.

Laboratory